Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment

PURPOSE: Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist used for treatment of chronic central serous chorioretinopathy which characterized by accumulation of subretinal fluid causing a localized area of retinal detachment. unfortunately, EPL suffers from poor oral bioavailabil...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Deliv
Autors principals: Abdelhakeem, Eman, El-Nabarawi, Mohamed, Shamma, Rehab
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8023249/
https://ncbi.nlm.nih.gov/pubmed/33787445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2021.1902023
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars